Determination of prognosis of Philadelphia chromosome‑negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution

Ito,Shinichi; Tsutsumi,Yutaka; Ohigashi,Hiroyuki; Shiratori,Souichi; Teshima,Takanori

doi:10.3892/mco.2015.652

Determination of prognosis of Philadelphia chromosome‑negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution

Authors:
- Shinichi Ito
- Yutaka Tsutsumi
- Hiroyuki Ohigashi
- Souichi Shiratori
- Takanori Teshima
View Affiliations

Affiliations: Department of Hematology, Hakodate Municipal Hospital, Hakodate, Hokkaido 041‑8680, Japan, Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060‑8638, Japan
Published online on: October 15, 2015 https://doi.org/10.3892/mco.2015.652
Pages: 51-57

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Philadelphia chromosome‑negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocytosis (ET) and primary myelofibrosis (PMF), are clonal hematopoietic diseases. A single‑institution retrospective analysis was performed, including 71 MPN patients diagnosed at the Hakodate Municipal Hospital between April, 2001 and April, 2014, and certain clinical characteristics were identified as effective prognostic factors. The patients were categorized by risk factor scoring based on age, number of abnormal blood cell lineages and splenomegaly at diagnosis, and the association between this categorization and prognosis was analyzed using a statistical procedure. the effect of Janus kinase 2 (JAK2) V617F mutation on prognosis was also investigated. The MPN patients were consolidated into three risk groups based on the margin of intergroup survival differences: i) score 1‑2 (n=23), ii) score 3 (n=24) and iii) score 4‑5 (n=24). MPN patients with scores of 4 or 5 exhibited poorer overall survival (OS) compared with those with lower scores (P<0.001). In addition, there were significant differences in event‑free survival (EFS) among scoring groups (P=0.0059). PV and ET had a better prognosis compared with PMF, although this analysis suggested that PV and ET patients with scores of 4 or 5 may have a poorer prognosis in terms of OS (P=0.0052) and EFS (P=0.022) and should be closely followed up. We observed no significant prognostic effect of the JAK2V167F mutation for OS (P=0.28) or EFS (P=0.17). Our results suggested that a simple scoring system based on age, blood cell counts and presence of splenomegaly at diagnosis may be used for the long‑term prognosis of MPN patients.

View Figures

View References

1	Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
2	Streiff MB, Smith B and Spivak JL: The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: A survey of American Society of Hematology members' practice patterns. Blood. 99:1144–1149. 2002. View Article : Google Scholar : PubMed/NCBI
3	Tefferi A: Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 88:507–516. 2013. View Article : Google Scholar : PubMed/NCBI
4	Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, et al: DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 29:392–397. 2011. View Article : Google Scholar : PubMed/NCBI
5	Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
6	Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, et al: Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators: JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 123:1544–1551. 2014. View Article : Google Scholar : PubMed/NCBI
7	Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A and Vannucchi AM: Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators: Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 123:1552–1555. 2014. View Article : Google Scholar : PubMed/NCBI
8	Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, et al: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 369:2391–2405. 2013. View Article : Google Scholar : PubMed/NCBI
9	Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, et al: Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 369:2379–2390. 2013. View Article : Google Scholar : PubMed/NCBI
10	Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW: WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization (4th). (Lyon). IARC Press. 2008.
11	Tanaka R, Kuroda J, Stevenson W, Ashihara E, Ishikawa T, Taki T, Kobayashi Y, Kamitsuji Y, Kawata E, Takeuchix M, et al: Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res. 32:1462–1467. 2008. View Article : Google Scholar : PubMed/NCBI
12	Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G and Barbui T: Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 23:2224–2232. 2005. View Article : Google Scholar : PubMed/NCBI
13	Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, et al: A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 115:1703–1708. 2010. View Article : Google Scholar : PubMed/NCBI
14	Hussein K, Pardanani AD, Van Dyke DL, Hanson CA and Tefferi A: International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 115:496–499. 2010. View Article : Google Scholar : PubMed/NCBI
15	Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H and Verstovsek S: The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood. 113:4171–4178. 2009. View Article : Google Scholar : PubMed/NCBI
16	Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, et al: Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients. Blood. 117:5857–5859. 2011. View Article : Google Scholar : PubMed/NCBI
17	Koppikar P and Levine RL: JAK2 and MPL mutations in myeloproliferative neoplasms. Acta Haematol. 119:218–225. 2008. View Article : Google Scholar : PubMed/NCBI
18	Levine RL and Gilliland DG: Myeloproliferative disorders. Blood. 112:2190–2198. 2008. View Article : Google Scholar : PubMed/NCBI
19	Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, et al: Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 115:2882–2890. 2010. View Article : Google Scholar : PubMed/NCBI
20	Cervantes F, Passamonti F and Barosi G: Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 22:905–914. 2008. View Article : Google Scholar : PubMed/NCBI
21	Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, et al: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 356:459–468. 2007. View Article : Google Scholar : PubMed/NCBI